Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | HTT | P42858 | 4/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14920301 | 0.83 | ALDH1A1 (0.50) | ALDH1A1HTTGAATDP1L3MBTL1 | |
| SCHEMBL14921239 | 0.83 | ALDH1A1 (0.53) | ALDH1A1HTTGAATDP1L3MBTL1 | |
| SCHEMBL17325379 | 0.82 | GRIN2B (0.38) | HTTTDP1L3MBTL1PLAUSMN1; SMN2 | |
| SCHEMBL29721809 | 0.81 | ALDH1A1 (0.55) | ALDH1A1HTTGAATDP1L3MBTL1 | |
| SCHEMBL12871592 | 0.77 | ALDH1A1 (0.50) | ALDH1A1HTTGAATDP1L3MBTL1 | |
| SCHEMBL11982024 | 0.75 | TDP1 (0.58) | ALDH1A1HTTGAATDP1L3MBTL1 | |
| SCHEMBL20181887 | 0.75 | ALDH1A1 (0.45) | ALDH1A1HTTGAATDP1L3MBTL1 | |
| SCHEMBL14920829 | 0.74 | ALDH1A1 (0.47) | ALDH1A1HTTGAATDP1L3MBTL1 | |
| SCHEMBL14932546 | 0.73 | ALDH1A1 (0.47) | ALDH1A1HTTGAATDP1L3MBTL1 | |
| SCHEMBL20271127 | 0.73 | HTT (0.36) | ALDH1A1HTTGAASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548903-B2 | Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use | AMGEN INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-11548903-B2 | Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use | AMGEN INC. (US) | 2023-01-10 | — | — | US | disclosed |
| EP-3555106-B1 | BICYCLIC THIAZINE AND OXAZINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC (US) | 2022-03-09 | — | — | EP | disclosed |
| EP-3555106-B1 | BICYCLIC THIAZINE AND OXAZINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC (US) | 2022-03-09 | — | — | EP | disclosed |
| US-11021493-B2 | 1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use | AMGEN INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-11021493-B2 | 1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use | AMGEN INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200231601-A1 | 1,4-THIAZINE DIOXIDE AND 1,2,4-THIADIAZINE DIOXIDE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2020-07-23 | — | — | US | disclosed |
| US-20200231601-A1 | 1,4-THIAZINE DIOXIDE AND 1,2,4-THIADIAZINE DIOXIDE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2020-07-23 | — | — | US | disclosed |
| US-20200199153-A1 | BICYCLIC THIAZINE AND OXAZINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2020-06-25 | — | — | US | disclosed |
| US-20200199153-A1 | BICYCLIC THIAZINE AND OXAZINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2020-06-25 | — | — | US | disclosed |
| EP-3555086-A1 | 1,4-THIAZINE DIOXIDE AND 1,2,4-THIADIAZINE DIOXIDE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | Amgen Inc. (US) | 2019-10-23 | — | — | EP | disclosed |
| WO-2018112084-A1 | BICYCLIC THIAZINE AND OXAZINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018112094-A1 | 1,4-THIAZINE DIOXIDE AND 1,2,4-THIADIAZINE DIOXIDE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018112094-A1 | 1,4-THIAZINE DIOXIDE AND 1,2,4-THIADIAZINE DIOXIDE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2018-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200199153-A1 | BICYCLIC THIAZINE AND OXAZINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | BACE1, BACE2, APP | ALDH1A1 1828/4885HTT 2010/4885GAA 25/4885 |
| US-20200231601-A1 | 1,4-THIAZINE DIOXIDE AND 1,2,4-THIADIAZINE DIOXIDE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | BACE1, BACE2, APP | ALDH1A1 930/4885HTT 1761/4885GAA 95/4885 |
| US-11021493-B2 | 1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use | BACE1, BACE2, APP | ALDH1A1 930/4885HTT 1761/4885GAA 95/4885 |
| US-11548903-B2 | Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use | BACE1, BACE2, APP | ALDH1A1 1828/4885HTT 2010/4885GAA 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.